Collegium Pharmaceutical reported net income of $21.8 million for the third quarter of 2026, a decrease from $31.5 million in the prior year period, despite a slight increase in product revenues to $216.3 million. The company completed the acquisition of Azstarys during the nine-month period, contributing to a significant increase in total assets to $2.1 billion and a rise in operating expenses due to higher selling, general, and administrative costs.
Collegium Pharmaceutical reported record Q3 2026 net revenue of $216.3 million, driven by strong performance in its ADHD portfolio, including record JORNAY PM sales and the first full quarter of AZSTARYS revenue. The company reaffirmed its full-year 2026 financial guidance and expects to complete its $50 million accelerated share repurchase program by year-end.
Term
Q3 2026
“We continued to see strong demand across our ADHD portfolio, supported by expanded commercial efforts heading into the back-to-school season. JORNAY PM reached record revenues, prescriptions and prescriber adoption, with quarterly net revenue growing 24% year-over-year.”
Vikram Karnani, President and Chief Executive Officer
“We generated a record $216.3 million in quarterly net revenue and $121.6 million in adjusted EBITDA, with our ADHD franchise now contributing more than 36% of total revenue.”